Tirzepatide - A Revolution in Obesity Treatment? [PDF]
Quality in SportIntroduction and aim of study: Obesity is a chronic disease associated with numerous health complications, and the number of patients is steadily increasing. Pharmacological methods for treating obesity are becoming increasingly popular. This paper aims
Aleksandra Jaroń +7 more
doaj +3 more sources
Tirzepatide Prescribing Practices and Efficacy in Patients with Diabetes and Chronic Kidney Disease at a Large Tertiary Care Center in the United States [PDF]
Diabetes, Metabolic Syndrome and ObesitySriya Amruta Kosaraju,1 Rong M Zhang2 1Department of Biomedical Sciences, University of Missouri-Kansas City, Kansas City, MO, USA; 2Department of Medicine-Division of Endocrinology, Washington University, St Louis, MO, USACorrespondence: Rong M Zhang ...
Kosaraju SA, Zhang RM
doaj +3 more sources
Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review [PDF]
Journal of Education, Health and Sport, 2023 Background: Obesity is a chronic disease, which along with its complications, poses a huge threat to both our health as individuals and our healthcare as a community.
Bartłomiej Stachyra +9 more
doaj +3 more sources
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program [PDF]
Cardiovascular DiabetologyBackground Metabolic syndrome is characterized as the co-occurrence of interrelated cardiovascular risk factors, including insulin resistance, hyperinsulinemia, abdominal obesity, dyslipidemia and hypertension.
Stephen J. Nicholls +9 more
doaj +3 more sources
Obesity medications and acquired hypothalamic obesity in adults: A two-case experience [PDF]
Obesity PillarsBackground: Acquired hypothalamic obesity (HO) lacks well-described adult pharmacotherapy outcomes, creating a unique clinical challenge for providers tasked with the treatment of patients with hypothalamic obesity.
Henry Lang +3 more
doaj +2 more sources
Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes [PDF]
Quality in SportThe increasing global prevalence of obesity and type 2 diabetes (T2D) has prompted significant advancements in pharmacological treatments, with glucagon-like peptide-1 (GLP-1) receptor agonists and dual agonists representing key innovations. Semaglutide,
Laura Opalska +7 more
doaj +3 more sources
Pharmacotherapy for chronic obesity management: a look into the future [PDF]
, 2023 Substantial leaps have been made in the drug discovery front in tackling the growing pandemic of obesity and its metabolic co-morbidities. Greater mechanistic insight and understanding of the gut-brain molecular pathways at play have enabled the pursuit ...
Abdel-Malek, Mariana +2 more
core +1 more source
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial [PDF]
, 2023 Background: Weight reduction is essential for improving health outcomes in people with obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor ...
core +1 more source
Cardiovascular Diabetology, 2023 Background Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 receptor agonist, is approved in the United States, Europe and Japan for the treatment of type 2 diabetes.
Ildiko Lingvay +6 more
doaj +1 more source
Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis [PDF]
Endocrinology and MetabolismBackground Data on the carcinogenic potential of tirzepatide from randomized controlled trials (RCTs) are limited. Furthermore, no meta-analysis has included all relevant RCTs to assess the cancer risk associated with tirzepatide.
A.B.M. Kamrul-Hasan +5 more
doaj +1 more source